BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 12132788)

  • 1. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
    Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
    Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
    Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
    Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
    N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice.
    Cadahia V; García-Carbonero A; Vivas S; Fuentes D; Niño P; Rebollo P; Rodrigo L
    Rev Esp Enferm Dig; 2004 Jun; 96(6):369-74; 374-8. PubMed ID: 15230666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to infliximab is related to disease duration in paediatric Crohn's disease.
    Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
    Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
    Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience.
    Arnott ID; McDonald D; Williams A; Ghosh S
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1639-46. PubMed ID: 11564005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
    Hanauer SB; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Rutgeerts P;
    Lancet; 2002 May; 359(9317):1541-9. PubMed ID: 12047962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
    Sands BE; Blank MA; Patel K; van Deventer SJ;
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):912-20. PubMed ID: 15476155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.